SV Life Sciences maintains ophthalmology focus by backing Imagen Biotech
This article was originally published in Scrip
SV Life Sciences reinforced its interest in backing biotechs focusing on ophthalmology by participating in the $40 million series A round closed by Imagen Biotech, a New York-based start-up. The financing round represents the fifth investment in an ophthalmology company this year, and the ninth one in the past three years. SV Life Sciences was joined by Novo Ventures and Fidelity Biosciences.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.